Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,039 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruš D, Rosti G, Stephenson AJ, Tandstad T. Oldenburg J, et al. Among authors: cullen m. Ann Oncol. 2015 May;26(5):833-838. doi: 10.1093/annonc/mdu514. Epub 2014 Nov 6. Ann Oncol. 2015. PMID: 25378299 Free article. Review.
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, deMulder P. Kaye SB, et al. Among authors: cullen m. J Clin Oncol. 1998 Feb;16(2):692-701. doi: 10.1200/JCO.1998.16.2.692. J Clin Oncol. 1998. PMID: 9469359 Clinical Trial.
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Fosså SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, De Mulder PH, Stenning S, Lallemand E, De Prijck L, Collette L. Fosså SD, et al. Among authors: cullen m. J Clin Oncol. 1998 Feb;16(2):716-24. doi: 10.1200/JCO.1998.16.2.716. J Clin Oncol. 1998. PMID: 9469362 Clinical Trial.
Adjuvant therapy for stage I testicular cancer.
Cullen M, James N. Cullen M, et al. Cancer Treat Rev. 1996 Jul;22(4):253-64. doi: 10.1016/s0305-7372(96)90019-5. Cancer Treat Rev. 1996. PMID: 9025783 Review. No abstract available.
A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA, Gabe R, Cafferty FH, Pollock P, White JD, Shamash J, Cullen MH, Stenning SP; TE23 Trial Management Group and Collaborators; National Cancer Research Institute Testis Cancer Clinical Studies Group. Huddart RA, et al. Eur Urol. 2015 Mar;67(3):534-43. doi: 10.1016/j.eururo.2014.06.034. Epub 2014 Jul 4. Eur Urol. 2015. PMID: 25001888 Free PMC article. Clinical Trial.
The management of seminoma.
Cullen M. Cullen M. Eur J Cancer. 1992;28A(11):1777-8. doi: 10.1016/0959-8049(92)90001-i. Eur J Cancer. 1992. PMID: 1389508 No abstract available.
Biology of testicular germ cell tumors.
Hussain SA, Ma YT, Palmer DH, Hutton P, Cullen MH. Hussain SA, et al. Expert Rev Anticancer Ther. 2008 Oct;8(10):1659-73. doi: 10.1586/14737140.8.10.1659. Expert Rev Anticancer Ther. 2008. PMID: 18925857 Review.
Biology of germ cell tumors.
Ma YT, Cullen MH, Hussain SA. Ma YT, et al. Hematol Oncol Clin North Am. 2011 Jun;25(3):457-71, vii. doi: 10.1016/j.hoc.2011.03.004. Epub 2011 Apr 13. Hematol Oncol Clin North Am. 2011. PMID: 21570602 Review.
1,039 results